University of British Columbia
Novel approaches for therapeutic modulation of gene expression in Huntington's disease
Abstract
dc:descriptionIntroduction: Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative disorder caused by a CAG triplet repeat expansion in exon 1 of the huntingtin gene (HTT). The mutation encodes an expanded polyglutamine tract in the huntingtin protein (HTT) that confers a toxic gain-of-function and drives HD pathogenesis. Despite its well-characterized etiology, there are no disease-modifying therapeutics for HD. Wild-type HTT is essential for embryonic development and functions in transcriptional regulation and vesicular transport. Mutant HTT retains a proportion of the functions of wild-type HTT, but also disrupts homeostatic processes including gene expression, intracellular transport, and protein clearance. Preclinical evidence demonstrates that wild-type HTT partially attenuates the deleterious effects of mutant HTT, and mutant HTT lowering improves HD-like phenotypes in cellular and animal models of HD. As a result, many ongoing efforts to develop HD therapies aim to reduce mutant HTT abundance. The clinical translation of these agents is limited by difficulties associated with selective mutant HTT lowering, and by a paucity of modalities that safely and effectively enable brain drug delivery. To address these challenges, we hypothesized that the HTT CAG expansion could function as a therapeutic target for selective mutant HTT lowering, and that lipid nanoparticle (LNP) technology could be adapted to improve the delivery of therapeutic nucleic acids to the brain. Methods: A putative allele-selective strategy for mutant HTT lowering, which deposits DNA methylation within the HTT exon 1 CAG repeat tract, was evaluated in a cellular HD model system. LNP technology was optimized to deliver two therapeutic nucleic acids, siRNA and mRNA, to primary neurons ex vivo. The application of this strategy for therapeutic use was explored using CRISPR-Cas9 genome editing in primary neurons. Results: The deposition of DNA methylation within the HTT exon 1 CAG repeat region reduced HTT expression, and optimized LNP formulations respectively improved the delivery of siRNA and mRNA to ex vivo primary neurons by 1.7-fold and over 24-fold. Conclusion: The results of this work indicate that DNA methylation at HTT may be a useful tool for the therapeutic modulation of HTT expression, and support the continued development of LNP-mediated brain gene therapy.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy - PhD
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Medical Genetics
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Thomson, Sarah Buckingham
- Contributors dc:contributor
-
- Leavitt, Blair R.
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/85652